Bezafibrate therapy has been shown to improve beta-oxidation of fatty acids and to reduce episodes of rhabdomyolysis in patients with carnitine palmitoyltransferase type-2 (CPT2) deficiency. This evidence concerns the gene CPT2 and hyperinsulinemic hypoglycemia, familial, 4.